{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Dopamine Hypothesis of Schizophrenia", "entry_form": "claim", "gradeable_restatement": "Excess dopamine transmission at D2 receptors in mesolimbic pathways is the primary cause of psychotic symptoms in schizophrenia.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Genotype, species, tissue, baseline eligibility and treatment timing fixed before outcomes", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Dopamine Hypothesis of Schizophrenia", "central_claim": "Excess dopamine transmission at D2 receptors in mesolimbic pathways is the primary cause of psychotic symptoms in schizophrenia.", "proposed_mechanism": "Excess dopamine transmission at D2 receptors in mesolimbic pathways is the primary cause of psychotic symptoms in schizophrenia.", "claimed_scope": "Unselected schizophrenia positive psychosis and specifically excess mesolimbic D2 signalling; association and symptom modulation kept separate", "claimed_level": [ "initiation", "progression" ], "is_conjunctive": true, "conjunctive_note": "SC3 is the clinical causal claim at the registered scope; narrower molecular, treatment or inherited-syndrome findings cannot replace it. Primary-subclaim aggregation is fixed before grading." }, "rubric_routing": { "primary_rubric": "07-psychiatry-neuromodulation.md", "secondary_rubrics": [], "index_notes_applied": [ "SC3 is the clinical causal claim at the registered scope; narrower molecular, treatment or inherited-syndrome findings cannot replace it. Primary-subclaim aggregation is fixed before grading." ], "rubric_fit_note": "07-psychiatry-neuromodulation governs clinical psychotic-symptom mechanism claims. Positive-symptom ratings are relevant because the nominal claim is symptomatic, not functional recovery. Registration and expectancy/mediator-control requirements are retained. The strict SC2 audit remains bounded by access/provenance and should not be generalized into a negative claim about established clinical drug efficacy." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Schizophrenia psychosis is associated with altered striatal dopamine synthesis or release.", "subclaim_type": "existence", "scope": "Anatomical compartment and treatment status defined before outcome", "claimed_scope": "Anatomical compartment and treatment status defined before outcome", "governing_rubric": "07-psychiatry-neuromodulation.md", "key_evidence_anchor": "PET synthesis/release and longitudinal at-risk cohorts", "hsef_level": "Β", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Imaging, depletion-derived binding and prospective risk studies reproducibly associate striatal dopamine differences with clinical state, with substantial compartment/treatment heterogeneity. The registered SC1 is an association/existence clause; its rating does not claim a causal disease dependency." }, { "id": "SC2", "statement": "Dopamine/D2 pathway manipulation causally changes psychotic symptom trajectories.", "subclaim_type": "mechanism", "scope": "Diagnosed psychosis with objective trajectory, target engagement and credible comparator", "claimed_scope": "Diagnosed psychosis with objective trajectory, target engagement and credible comparator", "governing_rubric": "07-psychiatry-neuromodulation.md", "key_evidence_anchor": "Depletion/challenge and controlled antipsychotic treatment", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Clinical challenge, drug-dose and occupancy studies support symptom modulation, but this bounded audit has not verified the psychiatry rubric combination of prespecified/registered primary symptom outcomes, credible expectancy controls and selective human D2 mediator manipulation. Occupancy-response correlation alone is insufficient. Γ here records an incompletely crossed strict mechanistic audit gate, not absence of antipsychotic efficacy or evidence that dopamine manipulation has no effects." }, { "id": "SC3", "statement": "Excess mesolimbic D2 signaling is the primary cause of schizophrenia psychotic symptoms.", "subclaim_type": "primacy", "scope": "Unselected schizophrenia psychosis, not retrospectively defined treatment responders", "claimed_scope": "Unselected schizophrenia psychosis, not retrospectively defined treatment responders", "governing_rubric": "07-psychiatry-neuromodulation.md", "key_evidence_anchor": "Specific human mediator manipulation and competing-pathway contrasts", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Human mesolimbic primacy in unselected schizophrenia remains unestablished. Associative-striatal findings, response/state heterogeneity and upstream rodent manipulations constrain the claim. Treatment benefit and premorbid synthesis elevation neither identify a universally primary mesolimbic cause nor prove dopamine is irrelevant." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "SC3 is the clinical causal claim at the registered scope; narrower molecular, treatment or inherited-syndrome findings cannot replace it. Primary-subclaim aggregation is fixed before grading.", "primary_subclaim_id": "SC3", "aggregation_derivation": "Overall Γ follows registered SC3, with association SC1 at Β and a conservative Γ for the strictly audited SC2 mechanism gate. The nominal claim fixes mesolimbic anatomy and unselected primacy, whereas strong human findings often concern associative striatum or symptom-responsive contexts. Clinical symptom modulation remains supported; the unresolved exact causal-primacy claim cannot be rescued by changing the anatomical label or retrospectively selecting responders.", "aggregation_alternatives": { "weakest_link_would_return": "Β", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Separate narrow successes do not replace the preregistered gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M4", "is_nominal": false, "name": "Heterogeneous psychosis pathways", "core_claim": "Different states/subgroups combine dopamine and other circuit mechanisms.", "explains_what_nominal_does_not": "Different states/subgroups combine dopamine and other circuit mechanisms.", "strongest_supporting_evidence": [ "TRS, remission, compartment and STRATA findings reveal nonuniform neurochemistry." ], "strongest_contradictory_evidence": [ "Heterogeneity does not itself establish every proposed subtype mechanism." ], "hsef_level_for_this_model": "Γ", "rationale": "TRS, remission, compartment and STRATA findings reveal nonuniform neurochemistry. Heterogeneity does not itself establish every proposed subtype mechanism." }, { "rank_in_tournament": 2, "model_id": "M2", "is_nominal": false, "name": "Downstream dopamine mediator", "core_claim": "Upstream circuit/developmental changes converge partly on dopamine-mediated positive symptoms.", "explains_what_nominal_does_not": "Upstream circuit/developmental changes converge partly on dopamine-mediated positive symptoms.", "strongest_supporting_evidence": [ "Prospective synthesis, challenge response and upstream rodent perturbations support this account." ], "strongest_contradictory_evidence": [ "Not all human upstream-to-dopamine pathways or symptom dependency are selectively established." ], "hsef_level_for_this_model": "Γ", "rationale": "Prospective synthesis, challenge response and upstream rodent perturbations support this account. Not all human upstream-to-dopamine pathways or symptom dependency are selectively established." }, { "rank_in_tournament": 3, "model_id": "M3", "is_nominal": false, "name": "Glutamate/neurodevelopmental upstream mechanisms", "core_claim": "Cortical/hippocampal dysfunction can generate downstream dopamine changes.", "explains_what_nominal_does_not": "Cortical/hippocampal dysfunction can generate downstream dopamine changes.", "strongest_supporting_evidence": [ "DISC1/parvalbumin/Cyclin-D2 models and modest ACC glutamate differences support plausibility." ], "strongest_contradictory_evidence": [ "Rodent proxies and clinical correlations do not prove a universal human alternative." ], "hsef_level_for_this_model": "Γ", "rationale": "DISC1/parvalbumin/Cyclin-D2 models and modest ACC glutamate differences support plausibility. Rodent proxies and clinical correlations do not prove a universal human alternative." }, { "rank_in_tournament": 4, "model_id": "M1", "is_nominal": true, "name": "Mesolimbic D2 primacy", "core_claim": "Excess mesolimbic D2 signalling primarily causes schizophrenia psychotic symptoms.", "explains_what_nominal_does_not": "Excess mesolimbic D2 signalling primarily causes schizophrenia psychotic symptoms.", "strongest_supporting_evidence": [ "D2 treatment-response relations and dopamine challenge give a substantial steelman." ], "strongest_contradictory_evidence": [ "Anatomical, clinical-state and resistance boundaries block unselected primacy." ], "hsef_level_for_this_model": "Γ", "rationale": "D2 treatment-response relations and dopamine challenge give a substantial steelman. Anatomical, clinical-state and resistance boundaries block unselected primacy." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. Demjaha treatment-response comparison (PMID23034655) favors heterogeneity over a uniform pathway; STRATA (PMID32910150) fails to reproduce a clear dopamine responder separator and prevents turning a small-study result into a settled subtype classifier. The strongest rank-1/rank-2 distinction remains imperfect because heterogeneous pathways can include downstream dopamine mediation.", "study_separating_rank1_from_rank2": "Demjaha treatment-response comparison (PMID23034655) favors heterogeneity over a uniform pathway; STRATA (PMID32910150) fails to reproduce a clear dopamine responder separator and prevents turning a small-study result into a settled subtype classifier. The strongest rank-1/rank-2 distinction remains imperfect because heterogeneous pathways can include downstream dopamine mediation.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "31188232", "title": "Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial.", "citation": "Ozawa C, Bies RR, Pillai N et al. Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial. Journal of clinical psychopharmacology. 2019.", "doi": "10.1097/JCP.0000000000001046", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31188232/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31188232/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID31188232", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Randomized model-guided dose reduction maintains several outcomes but increases selected worsening signals.", "what_it_does_not_show": "Small single-blind pilot, modeled occupancy and endpoint differences; no mesolimbic primacy test.", "confounders_present": [ "Small single-blind pilot, modeled occupancy and endpoint differences; no mesolimbic primacy test." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 2, "pmid": "24073841", "title": "D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.", "citation": "Potkin SG, Keator DB, Kesler-West ML et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS spectrums. 2014.", "doi": "10.1017/S109285291300059X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24073841/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24073841/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID24073841", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Lurasidone exposure and D2 occupancy associate with positive-symptom improvement.", "what_it_does_not_show": "Occupancy-outcome correlation and variable concentrations do not manipulate a selective symptom mediator independently.", "confounders_present": [ "Occupancy-outcome correlation and variable concentrations do not manipulate a selective symptom mediator independently." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 3, "pmid": "23899638", "title": "Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.", "citation": "Moriguchi S, Bies RR, Remington G et al. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Journal of clinical psychopharmacology. 2013.", "doi": "10.1097/JCP.0b013e3182979a0a", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/23899638/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23899638/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID25719960" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID23899638", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Selected CATIE remitters often lack continuous estimated occupancy above the proposed threshold.", "what_it_does_not_show": "Modeled occupancy and remission selection; linked erratum retained, no universal numerical threshold asserted.", "confounders_present": [ "Modeled occupancy and remission selection; linked erratum retained, no universal numerical threshold asserted." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 4, "pmid": "9659858", "title": "5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.", "citation": "Kapur S, Zipursky RB, Remington G et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. The American journal of psychiatry. 1998.", "doi": "10.1176/ajp.155.7.921", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/9659858/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9659858/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID9659858", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Olanzapine occupies both serotonin and D2 receptors with dose-dependent D2 binding.", "what_it_does_not_show": "Multireceptor exposure and imaging alone do not isolate the clinical mediator.", "confounders_present": [ "Multireceptor exposure and imaging alone do not isolate the clinical mediator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 5, "pmid": "22230651", "title": "Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.", "citation": "Mizuno Y, Bies RR, Remington G et al. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in neuro-psychopharmacology & biological psychiatry. 2012.", "doi": "10.1016/j.pnpbp.2011.12.013", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/22230651/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22230651/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID22230651", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Stable patients often have estimated D2 occupancy below a continuously maintained conventional threshold.", "what_it_does_not_show": "Cross-sectional survivor selection and estimated concentrations; does not establish zero D2 contribution.", "confounders_present": [ "Cross-sectional survivor selection and estimated concentrations; does not establish zero D2 contribution." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 6, "pmid": "17077809", "title": "Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.", "citation": "Agid O, Mamo D, Ginovart N et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2007.", "doi": "10.1038/sj.npp.1301242", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17077809/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17077809/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID17077809", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Double-blind PET treatment study links striatal rather than extrastriatal occupancy with positive-symptom response.", "what_it_does_not_show": "Regional occupancies correlate and mediator is not independently randomized; no proof of specifically mesolimbic primacy.", "confounders_present": [ "Regional occupancies correlate and mediator is not independently randomized; no proof of specifically mesolimbic primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 7, "pmid": "16127964", "title": "Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.", "citation": "Zipursky RB, Christensen BK, Daskalakis Z et al. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005.", "doi": "10.1177/070674370505000806", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16127964/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16127964/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID16127964", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Olanzapine/haloperidol first-episode treatment shows response with similar adjusted D2 occupancy.", "what_it_does_not_show": "Active drugs differ in other receptors; small sample and mediator correlation do not identify universal disease cause.", "confounders_present": [ "Active drugs differ in other receptors; small sample and mediator correlation do not identify universal disease cause." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 8, "pmid": "25099201", "title": "Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.", "citation": "Takeuchi H, Suzuki T, Bies RR et al. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. The Journal of clinical psychiatry. 2014.", "doi": "10.4088/JCP.13m08841", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25099201/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25099201/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID25099201", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Randomized dose reduction lowers estimated occupancy with few short-term relapses.", "what_it_does_not_show": "Open-label small maintenance sample and model estimates; acute-onset efficacy and long-term necessity differ.", "confounders_present": [ "Open-label small maintenance sample and model estimates; acute-onset efficacy and long-term necessity differ." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 9, "pmid": "12562577", "title": "Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.", "citation": "de Haan L, van Bruggen M, Lavalaye J et al. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. The American journal of psychiatry. 2003.", "doi": "10.1176/appi.ajp.160.2.303", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12562577/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12562577/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID12562577", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Double-blind active-drug comparison links D2 occupancy range with subjective experience.", "what_it_does_not_show": "Subjective experience is not psychotic-symptom primacy; drug pleiotropy and unverified blinding integrity remain.", "confounders_present": [ "Subjective experience is not psychotic-symptom primacy; drug pleiotropy and unverified blinding integrity remain." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 10, "pmid": "10739409", "title": "Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.", "citation": "Kapur S, Zipursky R, Jones C et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. The American journal of psychiatry. 2000.", "doi": "10.1176/appi.ajp.157.4.514", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10739409/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10739409/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID10739409", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Double-blind haloperidol PET study links D2 occupancy with response and adverse effects.", "what_it_does_not_show": "Small historical study; measured mediator correlation, registration and expectancy controls are incompletely verified.", "confounders_present": [ "Small historical study; measured mediator correlation, registration and expectancy controls are incompletely verified." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 11, "pmid": "17728427", "title": "Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.", "citation": "Mamo D, Graff A, Mizrahi R et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. The American journal of psychiatry. 2007.", "doi": "10.1176/appi.ajp.2007.06091479", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17728427/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17728427/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID17728427", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Aripiprazole shows high D2 occupancy with a different adverse-effect profile from antagonists.", "what_it_does_not_show": "Partial agonism means occupancy is not equivalent to blockade; no universal threshold or initiating mechanism.", "confounders_present": [ "Partial agonism means occupancy is not equivalent to blockade; no universal threshold or initiating mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 12, "pmid": "10839333", "title": "A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.", "citation": "Kapur S, Zipursky R, Jones C et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Archives of general psychiatry. 2000.", "doi": "10.1001/archpsyc.57.6.553", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10839333/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10839333/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID10839333", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Quetiapine response occurs with transiently high rather than sustained D2 occupancy.", "what_it_does_not_show": "Preliminary open treatment and other-receptor/nonpharmacological effects require controls.", "confounders_present": [ "Preliminary open treatment and other-receptor/nonpharmacological effects require controls." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 13, "pmid": "32910150", "title": "Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA).", "citation": "Egerton A, Murphy A, Donocik J et al. Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). Schizophrenia bulletin. 2021.", "doi": "10.1093/schbul/sbaa128", "pmcid": "PMC7965076", "url": "https://pubmed.ncbi.nlm.nih.gov/32910150/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32910150/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID32910150", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph3, 1:Methods:paragraph4, 2:Results:paragraph11. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "null", "what_it_shows": "Multicentre STRATA does not find a responder/nonresponder dopamine-synthesis difference; ACC glutamate difference is modest.", "what_it_does_not_show": "Clinical group definitions and site heterogeneity constrain sensitivity; does not prove all resistance is nondopaminergic.", "confounders_present": [ "Clinical group definitions and site heterogeneity constrain sensitivity; does not prove all resistance is nondopaminergic." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 14, "pmid": "38691387", "title": "Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.", "citation": "Kaul I, Sawchak S, Walling DP et al. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA psychiatry. 2024.", "doi": "10.1001/jamapsychiatry.2024.0785", "pmcid": "PMC11063924", "url": "https://pubmed.ncbi.nlm.nih.gov/38691387/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38691387/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID38958995" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID38691387", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph5, 2:Results:paragraph7. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "EMERGENT-3 xanomeline-trospium improves prespecified symptom scores versus placebo.", "what_it_does_not_show": "Treatment-resistant history excluded; no dopamine mediator measurement, short follow-up and adverse-effect differences. Erratum retained.", "confounders_present": [ "Treatment-resistant history excluded; no dopamine mediator measurement, short follow-up and adverse-effect differences. Erratum retained." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [ "EMERGENT sponsor, drug and protocol family." ] }, { "n": 15, "pmid": "38104575", "title": "Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.", "citation": "Kaul I, Sawchak S, Correll CU et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet (London, England). 2024.", "doi": "10.1016/S0140-6736(23)02190-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38104575/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38104575/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID38823993" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID38104575", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "EMERGENT-2 meets primary symptom endpoint with muscarinic treatment versus placebo.", "what_it_does_not_show": "Same sponsor/program and short duration; not proof that dopamine is dispensable. Linked erratum not examined.", "confounders_present": [ "Same sponsor/program and short duration; not proof that dopamine is dispensable. Linked erratum not examined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [ "EMERGENT sponsor, drug and protocol family." ] }, { "n": 16, "pmid": "36528376", "title": "Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.", "citation": "Krystal JH, Kane JM, Correll CU et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet (London, England). 2022.", "doi": "10.1016/S0140-6736(22)01990-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/36528376/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36528376/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID36528376", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Early emraclidine trial tests M4 modulation with comparable overall adverse-event rates and preliminary efficacy signals.", "what_it_does_not_show": "Small phase-1b sample and exploratory efficacy; cannot establish later confirmatory success or unselected mechanism primacy.", "confounders_present": [ "Small phase-1b sample and exploratory efficacy; cannot establish later confirmatory success or unselected mechanism primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 17, "pmid": "19054502", "title": "Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia.", "citation": "Prata DP, Mechelli A, Fu CH et al. Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia. Biological psychiatry. 2009.", "doi": "10.1016/j.biopsych.2008.09.027", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19054502/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19054502/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID19054502", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "COMT genotype has opposite cortical activation associations in controls and patients.", "what_it_does_not_show": "Genotype/fMRI association, task and medication effects are not selective D2 psychosis causation.", "confounders_present": [ "Genotype/fMRI association, task and medication effects are not selective D2 psychosis causation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 18, "pmid": "20188653", "title": "Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits.", "citation": "Niwa M, Kamiya A, Murai R et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron. 2010.", "doi": "10.1016/j.neuron.2010.01.019", "pmcid": "PMC3084528", "url": "https://pubmed.ncbi.nlm.nih.gov/20188653/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20188653/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID20188653", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "experimental model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Early cortical DISC1 knockdown alters later mesocortical dopamine maturation and behaviour.", "what_it_does_not_show": "Developmental gene-transfer model and rodent behavioural proxies do not establish the registered human primary mechanism.", "confounders_present": [ "Developmental gene-transfer model and rodent behavioural proxies do not establish the registered human primary mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 19, "pmid": "21187413", "title": "DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.", "citation": "Blasi G, Napolitano F, Ursini G et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2011.", "doi": "10.1073/pnas.1013535108", "pmcid": "PMC3024671", "url": "https://pubmed.ncbi.nlm.nih.gov/21187413/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21187413/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID21187413", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "DRD2/AKT1 interaction associates with molecular, attentional and olanzapine-response phenotypes.", "what_it_does_not_show": "Candidate genetic interaction and correlated outcomes require independent validation; no selective mediator perturbation.", "confounders_present": [ "Candidate genetic interaction and correlated outcomes require independent validation; no selective mediator perturbation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 20, "pmid": "30958880", "title": "D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients.", "citation": "Stenkrona P, Matheson GJ, Halldin C et al. D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients. The international journal of neuropsychopharmacology. 2019.", "doi": "10.1093/ijnp/pyz017", "pmcid": "PMC6600463", "url": "https://pubmed.ncbi.nlm.nih.gov/30958880/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30958880/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID30958880", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Drug-naive first-episode patients show lower prefrontal D1 availability without a striatal difference.", "what_it_does_not_show": "D1 cortical biology differs from the claimed mesolimbic D2 pathway; group imaging is associational.", "confounders_present": [ "D1 cortical biology differs from the claimed mesolimbic D2 pathway; group imaging is associational." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 21, "pmid": "11063922", "title": "In vivo measurement of the vesicular monoamine transporter in schizophrenia.", "citation": "Taylor SF, Koeppe RA, Tandon R et al. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2000.", "doi": "10.1016/S0893-133X(00)00165-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/11063922/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/11063922/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID11063922", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "VMAT2 imaging does not support increased striatal terminal density in schizophrenia.", "what_it_does_not_show": "Terminal density and dopamine release are different measurements; small sample cannot exclude functional dysregulation.", "confounders_present": [ "Terminal density and dopamine release are different measurements; small sample cannot exclude functional dysregulation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 22, "pmid": "24526133", "title": "Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis.", "citation": "De Koning MB, Bloemen OJ, Van Duin ED et al. Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. Journal of psychopharmacology (Oxford, England). 2014.", "doi": "10.1177/0269881113519507", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24526133/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24526133/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID24526133", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "UHR PPI impairment does not correlate with measured depletion-derived synaptic dopamine.", "what_it_does_not_show": "Distinct proxy measures and small groups; no direct clinical primacy or therapeutic test.", "confounders_present": [ "Distinct proxy measures and small groups; no direct clinical primacy or therapeutic test." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 23, "pmid": "29717334", "title": "The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia.", "citation": "Veselinović T, Vernaleken I, Janouschek H et al. The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacology. 2018.", "doi": "10.1007/s00213-018-4916-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29717334/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29717334/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID29717334", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "D2/3 availability relates to selected cognitive performance without a significant overall group increase.", "what_it_does_not_show": "Cognition differs from positive psychosis; receptor availability mixes occupancy and density.", "confounders_present": [ "Cognition differs from positive psychosis; receptor availability mixes occupancy and density." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 24, "pmid": "31264367", "title": "Disrupted-in-schizophrenia 1 functional polymorphisms and D2 /D3 receptor availability: A [11 C]-(+)-PHNO imaging study.", "citation": "Dahoun T, Nour MM, Adams RA et al. Disrupted-in-schizophrenia 1 functional polymorphisms and D2 /D3 receptor availability: A [11 C]-(+)-PHNO imaging study. Genes, brain, and behavior. 2019.", "doi": "10.1111/gbb.12596", "pmcid": "PMC7105392", "url": "https://pubmed.ncbi.nlm.nih.gov/31264367/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31264367/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID31264367", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "Common DISC1 functional variants do not associate with striatal D2/3 availability in healthy volunteers.", "what_it_does_not_show": "Small selected genetic sample; null receptor binding does not exclude other DISC1 pathways.", "confounders_present": [ "Small selected genetic sample; null receptor binding does not exclude other DISC1 pathways." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 25, "pmid": "29016872", "title": "Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia.", "citation": "Kubota M, Nagashima T, Takano H et al. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia. The international journal of neuropsychopharmacology. 2017.", "doi": "10.1093/ijnp/pyx063", "pmcid": "PMC5737675", "url": "https://pubmed.ncbi.nlm.nih.gov/29016872/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29016872/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID29016872", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Ligand-binding ratios suggest altered D2 affinity states despite nonsignificant individual binding differences.", "what_it_does_not_show": "Indirect ratio and post-hoc regional tests; no selective causal symptom manipulation.", "confounders_present": [ "Indirect ratio and post-hoc regional tests; no selective causal symptom manipulation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 26, "pmid": "17652599", "title": "Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study.", "citation": "Kumakura Y, Cumming P, Vernaleken I et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007.", "doi": "10.1523/JNEUROSCI.0805-07.2007", "pmcid": "PMC6672729", "url": "https://pubmed.ncbi.nlm.nih.gov/17652599/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17652599/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID17652599", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "FDOPA modeling suggests elevated turnover with reduced steady-state storage in untreated patients.", "what_it_does_not_show": "Tracer kinetics and reference assumptions matter; synthesis, storage and receptor stimulation are not interchangeable.", "confounders_present": [ "Tracer kinetics and reference assumptions matter; synthesis, storage and receptor stimulation are not interchangeable." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 27, "pmid": "19124684", "title": "Elevated striatal dopamine function linked to prodromal signs of schizophrenia.", "citation": "Howes OD, Montgomery AJ, Asselin MC et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of general psychiatry. 2009.", "doi": "10.1001/archgenpsychiatry.2008.514", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19124684/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19124684/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID19124684", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Prodromal dopamine synthesis elevation localizes mainly to associative striatum and correlates with symptoms.", "what_it_does_not_show": "Case-control prodromal association is not proof of mesolimbic primacy or universal conversion.", "confounders_present": [ "Case-control prodromal association is not proof of mesolimbic primacy or universal conversion." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Related Howes prodromal imaging research/recruitment program; potential overlap with prospective follow-up." ] }, { "n": 28, "pmid": "26320194", "title": "Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.", "citation": "Zhang JP, Robinson DG, Gallego JA et al. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophrenia bulletin. 2015.", "doi": "10.1093/schbul/sbv116", "pmcid": "PMC4601717", "url": "https://pubmed.ncbi.nlm.nih.gov/26320194/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26320194/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID26320194", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "DRD2-locus variant associates with positive-symptom response during first-episode drug treatment.", "what_it_does_not_show": "Treatment randomized, genotype not; linked variants, multiple phenotypes and side effects restrict interpretation.", "confounders_present": [ "Treatment randomized, genotype not; linked variants, multiple phenotypes and side effects restrict interpretation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 29, "pmid": "30796187", "title": "Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain.", "citation": "Cassidy CM, Zucca FA, Girgis RR et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proceedings of the National Academy of Sciences of the United States of America. 2019.", "doi": "10.1073/pnas.1807983116", "pmcid": "PMC6421437", "url": "https://pubmed.ncbi.nlm.nih.gov/30796187/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30796187/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID30796187", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Neuromelanin MRI associates with striatal dopamine release and psychosis severity.", "what_it_does_not_show": "Proxy validity does not confer causal direction or establish a D2-specific mechanism.", "confounders_present": [ "Proxy validity does not confer causal direction or establish a D2-specific mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 30, "pmid": "39334510", "title": "Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment.", "citation": "Lenk HÇ, Koch E, O'Connell KS et al. Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment. Human genomics. 2024.", "doi": "10.1186/s40246-024-00673-x", "pmcid": "PMC11438281", "url": "https://pubmed.ncbi.nlm.nih.gov/39334510/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39334510/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID39334510", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "TRS GWAS finds polygenic association and a suggestive locus below genome-wide significance.", "what_it_does_not_show": "Suggestive genetic evidence is not a validated causal locus or selective dopamine mechanism.", "confounders_present": [ "Suggestive genetic evidence is not a validated causal locus or selective dopamine mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 31, "pmid": "32961543", "title": "A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach.", "citation": "Veronese M, Santangelo B, Jauhar S et al. A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2021.", "doi": "10.1038/s41386-020-00866-7", "pmcid": "PMC8115068", "url": "https://pubmed.ncbi.nlm.nih.gov/32961543/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32961543/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID32961543", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "FDOPA imaging discriminates treatment-response groups in limited datasets.", "what_it_does_not_show": "Small setting-dependent samples, potential recruitment overlap and retrospective group definitions; not a prospective treatment-selection trial.", "confounders_present": [ "Small setting-dependent samples, potential recruitment overlap and retrospective group definitions; not a prospective treatment-selection trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Response-group imaging datasets may overlap earlier PET samples; no automatic independent replication credit." ] }, { "n": 32, "pmid": "35791965", "title": "Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia.", "citation": "Frankle WG, Himes M, Mason NS et al. Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia. Biological psychiatry. 2022.", "doi": "10.1016/j.biopsych.2022.05.009", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35791965/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35791965/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID35791965", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Cortical dopamine-release deficits correlate inversely with dorsal caudate release in patients.", "what_it_does_not_show": "Compartment heterogeneity and association do not prove direction, universal dopamine excess or primary mesolimbic pathology.", "confounders_present": [ "Compartment heterogeneity and association do not prove direction, universal dopamine excess or primary mesolimbic pathology." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 33, "pmid": "24888524", "title": "A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia.", "citation": "Boley AM, Perez SM, Lodge DJ. A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. Schizophrenia research. 2014.", "doi": "10.1016/j.schres.2014.05.005", "pmcid": "PMC4099272", "url": "https://pubmed.ncbi.nlm.nih.gov/24888524/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24888524/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID24888524", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "experimental model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Reducing hippocampal parvalbumin causes downstream dopamine activity and amphetamine-response changes.", "what_it_does_not_show": "Gene knockdown and locomotor proxy show an upstream route in rodents, not the complete human symptom mechanism.", "confounders_present": [ "Gene knockdown and locomotor proxy show an upstream route in rodents, not the complete human symptom mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 34, "pmid": "20618446", "title": "Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia.", "citation": "Lipina TV, Niwa M, Jaaro-Peled H et al. Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes, brain, and behavior. 2010.", "doi": "10.1111/j.1601-183X.2010.00615.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20618446/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20618446/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID20618446", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal endogenous", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "DISC1 mutant mice show dopamine-related behavioural abnormalities modifiable by haloperidol.", "what_it_does_not_show": "Genetic model and PPI/hyperactivity are translational proxies; endogenous human rate limitation remains unshown.", "confounders_present": [ "Genetic model and PPI/hyperactivity are translational proxies; endogenous human rate limitation remains unshown." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 35, "pmid": "30301879", "title": "Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.", "citation": "Grimm CM, Aksamaz S, Schulz S et al. Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity. Translational psychiatry. 2018.", "doi": "10.1038/s41398-018-0268-6", "pmcid": "PMC6178344", "url": "https://pubmed.ncbi.nlm.nih.gov/30301879/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30301879/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID30301879", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal endogenous", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Cyclin-D2 knockout hyperactivity resists D1/D2 antagonism but responds to a glutamate-pathway agonist.", "what_it_does_not_show": "Rodent proxy and developmental deletion are not treatment-resistant human schizophrenia.", "confounders_present": [ "Rodent proxy and developmental deletion are not treatment-resistant human schizophrenia." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 36, "pmid": "34364897", "title": "Dopaminergic mechanisms underlying the expression of antipsychotic-induced dopamine supersensitivity in rats.", "citation": "Servonnet A, Allain F, Gravel-Chouinard A et al. Dopaminergic mechanisms underlying the expression of antipsychotic-induced dopamine supersensitivity in rats. Neuropharmacology. 2021.", "doi": "10.1016/j.neuropharm.2021.108747", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34364897/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34364897/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID34364897", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "experimental model", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Drug-withdrawal rat supersensitivity has distinct D1/D2 dependence; central dopamine increase alone is insufficient.", "what_it_does_not_show": "Treatment-induced adaptation differs from spontaneous human disease initiation and unselected psychotic symptoms.", "confounders_present": [ "Treatment-induced adaptation differs from spontaneous human disease initiation and unselected psychotic symptoms." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 37, "pmid": "31135051", "title": "Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms.", "citation": "Avram M, Brandl F, Cabello J et al. Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain : a journal of neurology. 2019.", "doi": "10.1093/brain/awz093", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31135051/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31135051/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID31135051", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Patients in positive-symptom remission show lower striatal synthesis and cognitive associations.", "what_it_does_not_show": "Treated/remitted cross-sectional state and statistical mediation do not establish initiating cause.", "confounders_present": [ "Treated/remitted cross-sectional state and statistical mediation do not establish initiating cause." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 38, "pmid": "17655830", "title": "Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia.", "citation": "Huttunen J, Heinimaa M, Svirskis T et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biological psychiatry. 2008.", "doi": "10.1016/j.biopsych.2007.04.017", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17655830/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17655830/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID17655830", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "First-degree relatives show higher striatal FDOPA uptake in a selected study.", "what_it_does_not_show": "Familial association and possible confounding; not a sufficient prediction of future psychosis.", "confounders_present": [ "Familial association and possible confounding; not a sufficient prediction of future psychosis." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 39, "pmid": "19056247", "title": "Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET.", "citation": "Nozaki S, Kato M, Takano H et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophrenia research. 2009.", "doi": "10.1016/j.schres.2008.11.006", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19056247/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19056247/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID19056247", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Drug-naive/free patients show regional synthesis elevation, mainly left caudate, with selected symptom correlations.", "what_it_does_not_show": "Small sample and multiple regions; not uniform excess or selective mesolimbic causality.", "confounders_present": [ "Small sample and multiple regions; not uniform excess or selective mesolimbic causality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 40, "pmid": "23034655", "title": "Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.", "citation": "Demjaha A, Murray RM, McGuire PK et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. The American journal of psychiatry. 2012.", "doi": "10.1176/appi.ajp.2012.12010144", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/23034655/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23034655/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID23034655", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Responders have elevated synthesis relative to TRS patients and controls, with no TRS/control difference.", "what_it_does_not_show": "Small chronically treated groups and response-defined sampling; medication effects and heterogeneity limit generalization.", "confounders_present": [ "Small chronically treated groups and response-defined sampling; medication effects and heterogeneity limit generalization." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 41, "pmid": "11682247", "title": "Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging.", "citation": "Voruganti L, Slomka P, Zabel P et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2001.", "doi": "10.1016/S0893-133X(01)00263-9", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/11682247/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/11682247/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID11682247", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "AMPT depletion induces variable dysphoria correlated with dopamine-binding changes.", "what_it_does_not_show": "Dysphoria rather than psychotic trajectory is the main endpoint; obvious subjective effects complicate blind comparisons.", "confounders_present": [ "Dysphoria rather than psychotic trajectory is the main endpoint; obvious subjective effects complicate blind comparisons." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 42, "pmid": "9619147", "title": "Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.", "citation": "Abi-Dargham A, Gil R, Krystal J et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. The American journal of psychiatry. 1998.", "doi": "10.1176/ajp.155.6.761", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/9619147/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9619147/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID9619147", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Amphetamine challenge replicates excess release and transient positive-symptom worsening in a second cohort.", "what_it_does_not_show": "Acute subjective challenge, limited registration/expectancy verification and catecholamine specificity; not mesolimbic primacy.", "confounders_present": [ "Acute subjective challenge, limited registration/expectancy verification and catecholamine specificity; not mesolimbic primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 43, "pmid": "20194823", "title": "Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.", "citation": "Kegeles LS, Abi-Dargham A, Frankle WG et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Archives of general psychiatry. 2010.", "doi": "10.1001/archgenpsychiatry.2010.10", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20194823/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20194823/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID20194823", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Depletion-derived excess synaptic dopamine appears in associative striatum, not limbic/sensorimotor regions.", "what_it_does_not_show": "Primary endpoint is receptor-binding inference; no selective symptom trajectory experiment.", "confounders_present": [ "Primary endpoint is receptor-binding inference; no selective symptom trajectory experiment." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 44, "pmid": "21426628", "title": "Striatal dopamine synthesis capacity in twins discordant for schizophrenia.", "citation": "Shotbolt P, Stokes PR, Owens SF et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychological medicine. 2011.", "doi": "10.1017/S0033291711000341", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/21426628/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21426628/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID21426628", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "Discordant twins and stable patients do not show elevated synthesis versus controls.", "what_it_does_not_show": "Low symptom levels, treatment and small sample restrict interpretation as an absolute vulnerability null.", "confounders_present": [ "Low symptom levels, treatment and small sample restrict interpretation as an absolute vulnerability null." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 45, "pmid": "28387222", "title": "Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.", "citation": "Eisenberg DP, Yankowitz L, Ianni AM et al. Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2017.", "doi": "10.1038/npp.2017.67", "pmcid": "PMC5603816", "url": "https://pubmed.ncbi.nlm.nih.gov/28387222/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28387222/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID28387222", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Medication versus placebo periods alter striatal blood flow with symptom and synthesis associations.", "what_it_does_not_show": "Physiological and mediator associations do not selectively isolate D2 necessity or premorbid cause.", "confounders_present": [ "Physiological and mediator associations do not selectively isolate D2 necessity or premorbid cause." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 46, "pmid": "9122236", "title": "Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.", "citation": "Breier A, Su TP, Saunders R et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America. 1997.", "doi": "10.1073/pnas.94.6.2569", "pmcid": "PMC20129", "url": "https://pubmed.ncbi.nlm.nih.gov/9122236/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9122236/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID9122236", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "PET challenge shows greater amphetamine-associated binding displacement, with primate calibration support.", "what_it_does_not_show": "Binding inference and acute drug response differ from spontaneous human disease dependency.", "confounders_present": [ "Binding inference and acute drug response differ from spontaneous human disease dependency." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 47, "pmid": "21768612", "title": "Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.", "citation": "Howes OD, Bose SK, Turkheimer F et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. The American journal of psychiatry. 2011.", "doi": "10.1176/appi.ajp.2011.11010160", "pmcid": "PMC3682447", "url": "https://pubmed.ncbi.nlm.nih.gov/21768612/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21768612/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID21768612", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHOD:paragraph2, 1:METHOD:paragraph5, 2:RESULTS:paragraph3, 2:RESULTS:paragraph4. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Prospective converters have elevated dopamine synthesis before psychosis, strongest in associative striatum.", "what_it_does_not_show": "Small transition cohort, transdiagnostic outcomes and no mediator intervention; not proved initiating primacy.", "confounders_present": [ "Small transition cohort, transdiagnostic outcomes and no mediator intervention; not proved initiating primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": true, "provider": "Scite", "retrieved_on": "2026-10-11", "tally": { "total": 257, "supporting": 18, "contrasting": 4, "mentioning": 234, "citingPublications": 356 }, "notable_contrasting_statements": [], "note": "Provider tally only. Returned snippets are outgoing references from this anchor, not incoming contrasting evidence. No grade inferred from counts; editorial notices were not returned." }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Related Howes prodromal imaging research/recruitment program; potential overlap with earlier cohort." ] }, { "n": 48, "pmid": "10884434", "title": "Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.", "citation": "Abi-Dargham A, Rodenhiser J, Printz D et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2000.", "doi": "10.1073/pnas.97.14.8104", "pmcid": "PMC16677", "url": "https://pubmed.ncbi.nlm.nih.gov/10884434/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10884434/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID10884434", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Depletion reveals higher dopamine occupancy in untreated patients and predicts later treatment response.", "what_it_does_not_show": "Occupancy and treatment-response correlation are not independent randomized symptom-mediator manipulation.", "confounders_present": [ "Occupancy and treatment-response correlation are not independent randomized symptom-mediator manipulation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 49, "pmid": "27857125", "title": "Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.", "citation": "Kim E, Howes OD, Veronese M et al. Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2017.", "doi": "10.1038/npp.2016.258", "pmcid": "PMC5312074", "url": "https://pubmed.ncbi.nlm.nih.gov/27857125/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27857125/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID27857125", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Symptom-matched clozapine-treated TRS patients show lower synthesis than first-line responders.", "what_it_does_not_show": "Small groups and differential medications cannot fully separate disease traits from treatment effects.", "confounders_present": [ "Small groups and differential medications cannot fully separate disease traits from treatment effects." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 50, "pmid": "39632880", "title": "Synaptotagmin-11 deficiency mediates schizophrenia-like behaviors in mice via dopamine over-transmission.", "citation": "Chen Y, Gu Y, Wang B et al. Synaptotagmin-11 deficiency mediates schizophrenia-like behaviors in mice via dopamine over-transmission. Nature communications. 2024.", "doi": "10.1038/s41467-024-54604-4", "pmcid": "PMC11618495", "url": "https://pubmed.ncbi.nlm.nih.gov/39632880/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39632880/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID39632880", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal endogenous", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Adolescent Syt11 deficiency or dopamine over-excitation produces persistent behavioural deficits with D2-intervention effects.", "what_it_does_not_show": "Age-defined engineered mouse model and social/behavioural proxies cannot establish unselected human mesolimbic primacy.", "confounders_present": [ "Age-defined engineered mouse model and social/behavioural proxies cannot establish unselected human mesolimbic primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 54, "verified": 54, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Β", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Pure association evidence — however large, however replicated — cannot exceed Β.", "specific_trigger": "Imaging, depletion-derived binding and prospective risk studies reproducibly associate striatal dopamine differences with clinical state, with substantial compartment/treatment heterogeneity. The registered SC1 is an association/existence clause; its rating does not claim a causal disease dependency.", "resulting_ceiling": "Β" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ.", "specific_trigger": "Human mesolimbic primacy in unselected schizophrenia remains unestablished. Associative-striatal findings, response/state heterogeneity and upstream rodent manipulations constrain the claim. Treatment benefit and premorbid synthesis elevation neither identify a universally primary mesolimbic cause nor prove dopamine is irrelevant.", "resulting_ceiling": "Γ" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Excess dopamine transmission at D2 receptors in mesolimbic pathways is the primary cause of psychotic symptoms in schizophrenia.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "Positive symptom ratings can be a clinical phenotype here, but acute occupancy, synthesis and statistical mediation alone cannot cross the mechanistic gate. Blinded drug-dose studies and challenges are not downgraded simply because they are human; their preregistration, acute-effect controls and precise mediator attribution are the unresolved verification boundary. Mouse behavioural results cross within model biology, while psychiatry rodent-proxy and universal scope rules limit the inference to human SC3.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "at least one of:\n- Active comparator matched for acute subjective effect, blinding integrity measured and reported\n- Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject\n- Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia\n- Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker\n- Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors\n\nRating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "SC1 is primarily imaging, binding and symptom association.", "Historical challenges have acute subjective effects and incompletely verified outcome-registration/expectancy safeguards; occupancy correlations do not independently manipulate the proposed clinical mediator.", "Rodent developmental and behavioural results do not satisfy unselected human primacy. KarXT clinical efficacy does not demonstrate dopamine dispensability or direct D2 mediator engagement." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Imaging, depletion-derived binding and prospective risk studies reproducibly associate striatal dopamine differences with clinical state, with substantial compartment/treatment heterogeneity. The registered SC1 is an association/existence clause; its rating does not claim a causal disease dependency.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "at least one of:\n- Active comparator matched for acute subjective effect, blinding integrity measured and reported\n- Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject\n- Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia\n- Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker\n- Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors\n\nRating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "SC1 is primarily imaging, binding and symptom association.", "Historical challenges have acute subjective effects and incompletely verified outcome-registration/expectancy safeguards; occupancy correlations do not independently manipulate the proposed clinical mediator.", "Rodent developmental and behavioural results do not satisfy unselected human primacy. KarXT clinical efficacy does not demonstrate dopamine dispensability or direct D2 mediator engagement." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Clinical challenge, drug-dose and occupancy studies support symptom modulation, but this bounded audit has not verified the psychiatry rubric combination of prespecified/registered primary symptom outcomes, credible expectancy controls and selective human D2 mediator manipulation. Occupancy-response correlation alone is insufficient. Γ here records an incompletely crossed strict mechanistic audit gate, not absence of antipsychotic efficacy or evidence that dopamine manipulation has no effects.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "at least one of:\n- Active comparator matched for acute subjective effect, blinding integrity measured and reported\n- Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject\n- Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia\n- Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker\n- Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors\n\nRating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "SC1 is primarily imaging, binding and symptom association.", "Historical challenges have acute subjective effects and incompletely verified outcome-registration/expectancy safeguards; occupancy correlations do not independently manipulate the proposed clinical mediator.", "Rodent developmental and behavioural results do not satisfy unselected human primacy. KarXT clinical efficacy does not demonstrate dopamine dispensability or direct D2 mediator engagement." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Human mesolimbic primacy in unselected schizophrenia remains unestablished. Associative-striatal findings, response/state heterogeneity and upstream rodent manipulations constrain the claim. Treatment benefit and premorbid synthesis elevation neither identify a universally primary mesolimbic cause nor prove dopamine is irrelevant.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Selective prospective mediator perturbation tied to clinical psychotic trajectory would be required for a causal claim beyond this registered association clause." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Verify a prospectively registered primary symptom trajectory under selective D2/dopamine manipulation with credible acute-effect/expectancy controls and blinded assessors; recover protocol/registration evidence for historical challenges rather than assume it exists." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Predefine anatomy and eligibility in unselected psychosis, measure selective target engagement, compare competing pathway interventions and test necessity, initiating precedence and rate limitation without redefining scope from responders." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Prospective converters show associative but not significant limbic-striatal differences.", "STRATA shows no responder/nonresponder dopamine difference.", "Stable/remitted patients and discordant twins can lack increased synthesis.", "Continuous occupancy thresholds fail as universal maintenance rules; aripiprazole occupancy differs from antagonism." ], "note": "Treatment status, positive-symptom state, compartment and resistant-versus-responsive comparisons map boundaries. Group differences do not prospectively validate a response-selected human causal subtype. No post-hoc restriction replaces registered unselected SC3." }, "falsification_patterns_met": [ { "pattern": "Persistence or clinical heterogeneity despite the proposed uniform mechanism", "evidence": "TRS, remitted-state and occupancy exceptions constrain uniform primacy; STRATA also prevents overclaiming a simple rival subtype classification.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "pitfall": "Therapeutic mediator equated with initiating primary cause", "where": "Occupancy and symptom response do not establish unselected primacy." }, { "pitfall": "Anatomical relabeling", "where": "Associative/dorsal findings cannot silently substitute for mesolimbic SC3." }, { "pitfall": "Response-defined scope rescue", "where": "Retrospective responders and TRS contrasts do not replace unselected eligibility." } ], "causal_tally_audit": { "tally_claimed_by_document": 0, "tally_after_audit": 0, "tally_unit": "Positive qualifying study units across scoped subclaims, not independent causal lines or full-claim necessity/sufficiency.", "screened_discriminating_contrasts": 18, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Reports sharing recruitment, instruments or randomization are not automatically independent causal lines.", "The tally includes discriminating contrasts; positive qualifying source lists alone determine threshold crossings." ] }, "steelman": { "case_one_rung_higher": "One rung above, Δ: acute dopamine challenge worsens positive symptoms and D2 drug exposure predicts improvement, making a causal contribution very plausible. Yet SC3 asks specifically for unselected mesolimbic primacy, not some striatal contribution. Anatomical localization and selective initiating/rate-limiting evidence are missing; the strict SC2 registration/expectancy audit is also incomplete.", "case_one_rung_lower": "One rung below, Β: the strongest premorbid and treatment-stratification findings are observational. However, receptor pharmacology, human challenges and developmental-model perturbations provide substantial partial-system mechanistic support. Γ preserves that support while rejecting clinical primacy transfer.", "which_rejected": "Retain Γ for exact SC3. Do not relabel associative striatum as mesolimbic, equate therapeutic mediation with etiology, or conclude that a conservative mechanism audit invalidates demonstrated symptom benefit.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: Prospectively register a selective human dopamine/D2 mediator comparison in anatomically and clinically predefined psychosis strata, measure target engagement and acute-effect expectancy/blinding, use blinded symptom trajectories and an orthogonal nondopaminergic comparator, and prospectively test responses without selecting eligibility from observed treatment outcome." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "50 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Overall Γ follows registered SC3, with association SC1 at Β and a conservative Γ for the strictly audited SC2 mechanism gate. The nominal claim fixes mesolimbic anatomy and unselected primacy, whereas strong human findings often concern associative striatum or symptom-responsive contexts. Clinical symptom modulation remains supported; the unresolved exact causal-primacy claim cannot be rescued by changing the anatomical label or retrospectively selecting responders." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": 5, "derivation": "Dopamine differences can precede frank psychosis, so they are not established as solely a consequence of that phenotype. Challenge and treatment evidence supports a modifiable pathway in selected contexts, beyond co-occurrence alone. Unselected mesolimbic initiation, prevention and rate limitation are not jointly shown, and universal necessity is contradicted or unresolved. Step 5 assigns a context-limited symptom amplifier/mediator; it does not establish a universal upstream root cause.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "Syt11 conditional developmental perturbation (PMID39632880, 2024) tests initiation and D2 intervention in mice, while EMERGENT-3 (NCT04738123) tests symptom therapy. The first has rodent proxy/scope limits and the latter excludes TRS and lacks dopamine mediator measurement; neither crosses unselected human SC3.", "justification": "Syt11 conditional developmental perturbation (PMID39632880, 2024) tests initiation and D2 intervention in mice, while EMERGENT-3 (NCT04738123) tests symptom therapy. The first has rodent proxy/scope limits and the latter excludes TRS and lacks dopamine mediator measurement; neither crosses unselected human SC3." }, "stability": { "value": "Stable", "trigger": "No verified named pending result that would change the registered full-scope grade was identified. This does not mean that no relevant trial exists.", "justification": "No verified named pending result that would change the registered full-scope grade was identified. This does not mean that no relevant trial exists." }, "divergence": { "implied_level": null, "implied_level_basis": "No single field-implied level is defensible from conflicting framings.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "No manufactured field consensus or arithmetic gap." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "Prospectively register a selective human dopamine/D2 mediator comparison in anatomically and clinically predefined psychosis strata, measure target engagement and acute-effect expectancy/blinding, use blinded symptom trajectories and an orthogonal nondopaminergic comparator, and prospectively test responses without selecting eligibility from observed treatment outcome.", "readout": "Prespecified positive-psychotic symptom course and anatomy-specific engagement, with functional outcome as a separate endpoint", "critical_control": "Expectancy, acute subjective effects, rater blinding, medication history, adherence and competing-pathway engagement", "supporting_result": "Selective pathway perturbation predicts and changes symptoms across the fixed unselected scope, with initiating precedence and rate-limiting evidence", "falsifying_result": "Symptoms persist despite adequate selective engagement, anatomy fails prospective prediction, or independent competing-pathway effects explain trajectory without required dopamine change" } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Associative and limbic striatum are distinct anatomical hypotheses.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Historical challenge registration, expectancy controls and selective mediator evidence need fuller source recovery.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Treatment resistance and symptomatic remission complicate uniform excess.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Muscarinic efficacy does not demonstrate dopamine dispensability; EMERGENT-3 excluded TRS.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Prospective mechanistic stratification needs independent validation rather than retrospective response-group discrimination.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-11", "reviewer": "Codex", "evidence_base_note": "50 primary reports; literature cutoff 2026-10-09; source examination UTC date 2026-10-12; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez, separately logged public original-body retrieval, and Consensus Pro browser searches. Provider output retained as observed browser text with citation-link mappings, or as previously exported connector documents where present. AI synthesis is not primary full-text verification. Consensus retrieved/included counts are not examined-primary counts. One Scite call covered five anchors: provider tallies and outgoing reference contexts, not audited incoming contrasting statements. One SciSpace discovery call returned supplementary leads; none added to the primary count. No independent blinded review.", "skill_version": "5.3", "validator_run": "PASS: exact archived HSEF v5.3 validator, rerun after final sealing.", "validator_warnings_addressed": "No warnings.", "limits": "Bounded critical review; not an exhaustive systematic review, complete-paper audit, independent scientific peer review or blinded calibration. HIV is an existing draft carried forward after a source checkpoint." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Ranking categorical verdict and index guidance were visible. No completed blinded calibration claimed." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Blinded dose comparisons, withdrawal/medication-placebo periods, prospective imaging and genetic associations were considered. They constrain different errors, but registration/expectancy separation and selective unselected mesolimbic clinical mediation remain incomplete in this source audit. This is an access/evidence-identification limit as well as a mechanistic scope limit; it does not prove that no stronger clinical study exists. Upper grades remain reachable with the required source verification." }, { "kind": "natural_experiment", "available": true, "why_not_sufficient": "Blinded dose comparisons, withdrawal/medication-placebo periods, prospective imaging and genetic associations were considered. They constrain different errors, but registration/expectancy separation and selective unselected mesolimbic clinical mediation remain incomplete in this source audit. This is an access/evidence-identification limit as well as a mechanistic scope limit; it does not prove that no stronger clinical study exists. Upper grades remain reachable with the required source verification." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Blinded dose comparisons, withdrawal/medication-placebo periods, prospective imaging and genetic associations were considered. They constrain different errors, but registration/expectancy separation and selective unselected mesolimbic clinical mediation remain incomplete in this source audit. This is an access/evidence-identification limit as well as a mechanistic scope limit; it does not prove that no stronger clinical study exists. Upper grades remain reachable with the required source verification." }, { "kind": "withdrawal_rechallenge", "available": true, "why_not_sufficient": "Blinded dose comparisons, withdrawal/medication-placebo periods, prospective imaging and genetic associations were considered. They constrain different errors, but registration/expectancy separation and selective unselected mesolimbic clinical mediation remain incomplete in this source audit. This is an access/evidence-identification limit as well as a mechanistic scope limit; it does not prove that no stronger clinical study exists. Upper grades remain reachable with the required source verification." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "Blinded dose comparisons, withdrawal/medication-placebo periods, prospective imaging and genetic associations were considered. They constrain different errors, but registration/expectancy separation and selective unselected mesolimbic clinical mediation remain incomplete in this source audit. This is an access/evidence-identification limit as well as a mechanistic scope limit; it does not prove that no stronger clinical study exists. Upper grades remain reachable with the required source verification." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 50, "claims_total": 54, "claims_verified": 54, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 50, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "Randomized model-guided dose reduction maintains several outcomes but increases selected worsening signals. Small single-blind pilot, modeled occupancy and endpoint differences; no mesolimbic primacy test.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C2", "text": "Lurasidone exposure and D2 occupancy associate with positive-symptom improvement. Occupancy-outcome correlation and variable concentrations do not manipulate a selective symptom mediator independently.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C3", "text": "Selected CATIE remitters often lack continuous estimated occupancy above the proposed threshold. Modeled occupancy and remission selection; linked erratum retained, no universal numerical threshold asserted.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C4", "text": "Olanzapine occupies both serotonin and D2 receptors with dose-dependent D2 binding. Multireceptor exposure and imaging alone do not isolate the clinical mediator.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C5", "text": "Stable patients often have estimated D2 occupancy below a continuously maintained conventional threshold. Cross-sectional survivor selection and estimated concentrations; does not establish zero D2 contribution.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C6", "text": "Double-blind PET treatment study links striatal rather than extrastriatal occupancy with positive-symptom response. Regional occupancies correlate and mediator is not independently randomized; no proof of specifically mesolimbic primacy.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C7", "text": "Olanzapine/haloperidol first-episode treatment shows response with similar adjusted D2 occupancy. Active drugs differ in other receptors; small sample and mediator correlation do not identify universal disease cause.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C8", "text": "Randomized dose reduction lowers estimated occupancy with few short-term relapses. Open-label small maintenance sample and model estimates; acute-onset efficacy and long-term necessity differ.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C9", "text": "Double-blind active-drug comparison links D2 occupancy range with subjective experience. Subjective experience is not psychotic-symptom primacy; drug pleiotropy and unverified blinding integrity remain.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C10", "text": "Double-blind haloperidol PET study links D2 occupancy with response and adverse effects. Small historical study; measured mediator correlation, registration and expectancy controls are incompletely verified.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C11", "text": "Aripiprazole shows high D2 occupancy with a different adverse-effect profile from antagonists. Partial agonism means occupancy is not equivalent to blockade; no universal threshold or initiating mechanism.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C12", "text": "Quetiapine response occurs with transiently high rather than sustained D2 occupancy. Preliminary open treatment and other-receptor/nonpharmacological effects require controls.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C13", "text": "Multicentre STRATA does not find a responder/nonresponder dopamine-synthesis difference; ACC glutamate difference is modest. Clinical group definitions and site heterogeneity constrain sensitivity; does not prove all resistance is nondopaminergic.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph3, 1:Methods:paragraph4, 2:Results:paragraph11. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C14", "text": "EMERGENT-3 xanomeline-trospium improves prespecified symptom scores versus placebo. Treatment-resistant history excluded; no dopamine mediator measurement, short follow-up and adverse-effect differences. Erratum retained.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph5, 2:Results:paragraph7. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C15", "text": "EMERGENT-2 meets primary symptom endpoint with muscarinic treatment versus placebo. Same sponsor/program and short duration; not proof that dopamine is dispensable. Linked erratum not examined.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C16", "text": "Early emraclidine trial tests M4 modulation with comparable overall adverse-event rates and preliminary efficacy signals. Small phase-1b sample and exploratory efficacy; cannot establish later confirmatory success or unselected mechanism primacy.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C17", "text": "COMT genotype has opposite cortical activation associations in controls and patients. Genotype/fMRI association, task and medication effects are not selective D2 psychosis causation.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C18", "text": "Early cortical DISC1 knockdown alters later mesocortical dopamine maturation and behaviour. Developmental gene-transfer model and rodent behavioural proxies do not establish the registered human primary mechanism.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C19", "text": "DRD2/AKT1 interaction associates with molecular, attentional and olanzapine-response phenotypes. Candidate genetic interaction and correlated outcomes require independent validation; no selective mediator perturbation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C20", "text": "Drug-naive first-episode patients show lower prefrontal D1 availability without a striatal difference. D1 cortical biology differs from the claimed mesolimbic D2 pathway; group imaging is associational.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C21", "text": "VMAT2 imaging does not support increased striatal terminal density in schizophrenia. Terminal density and dopamine release are different measurements; small sample cannot exclude functional dysregulation.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C22", "text": "UHR PPI impairment does not correlate with measured depletion-derived synaptic dopamine. Distinct proxy measures and small groups; no direct clinical primacy or therapeutic test.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C23", "text": "D2/3 availability relates to selected cognitive performance without a significant overall group increase. Cognition differs from positive psychosis; receptor availability mixes occupancy and density.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C24", "text": "Common DISC1 functional variants do not associate with striatal D2/3 availability in healthy volunteers. Small selected genetic sample; null receptor binding does not exclude other DISC1 pathways.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C25", "text": "Ligand-binding ratios suggest altered D2 affinity states despite nonsignificant individual binding differences. Indirect ratio and post-hoc regional tests; no selective causal symptom manipulation.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C26", "text": "FDOPA modeling suggests elevated turnover with reduced steady-state storage in untreated patients. Tracer kinetics and reference assumptions matter; synthesis, storage and receptor stimulation are not interchangeable.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C27", "text": "Prodromal dopamine synthesis elevation localizes mainly to associative striatum and correlates with symptoms. Case-control prodromal association is not proof of mesolimbic primacy or universal conversion.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C28", "text": "DRD2-locus variant associates with positive-symptom response during first-episode drug treatment. Treatment randomized, genotype not; linked variants, multiple phenotypes and side effects restrict interpretation.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C29", "text": "Neuromelanin MRI associates with striatal dopamine release and psychosis severity. Proxy validity does not confer causal direction or establish a D2-specific mechanism.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C30", "text": "TRS GWAS finds polygenic association and a suggestive locus below genome-wide significance. Suggestive genetic evidence is not a validated causal locus or selective dopamine mechanism.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C31", "text": "FDOPA imaging discriminates treatment-response groups in limited datasets. Small setting-dependent samples, potential recruitment overlap and retrospective group definitions; not a prospective treatment-selection trial.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C32", "text": "Cortical dopamine-release deficits correlate inversely with dorsal caudate release in patients. Compartment heterogeneity and association do not prove direction, universal dopamine excess or primary mesolimbic pathology.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C33", "text": "Reducing hippocampal parvalbumin causes downstream dopamine activity and amphetamine-response changes. Gene knockdown and locomotor proxy show an upstream route in rodents, not the complete human symptom mechanism.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C34", "text": "DISC1 mutant mice show dopamine-related behavioural abnormalities modifiable by haloperidol. Genetic model and PPI/hyperactivity are translational proxies; endogenous human rate limitation remains unshown.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C35", "text": "Cyclin-D2 knockout hyperactivity resists D1/D2 antagonism but responds to a glutamate-pathway agonist. Rodent proxy and developmental deletion are not treatment-resistant human schizophrenia.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C36", "text": "Drug-withdrawal rat supersensitivity has distinct D1/D2 dependence; central dopamine increase alone is insufficient. Treatment-induced adaptation differs from spontaneous human disease initiation and unselected psychotic symptoms.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C37", "text": "Patients in positive-symptom remission show lower striatal synthesis and cognitive associations. Treated/remitted cross-sectional state and statistical mediation do not establish initiating cause.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C38", "text": "First-degree relatives show higher striatal FDOPA uptake in a selected study. Familial association and possible confounding; not a sufficient prediction of future psychosis.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C39", "text": "Drug-naive/free patients show regional synthesis elevation, mainly left caudate, with selected symptom correlations. Small sample and multiple regions; not uniform excess or selective mesolimbic causality.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C40", "text": "Responders have elevated synthesis relative to TRS patients and controls, with no TRS/control difference. Small chronically treated groups and response-defined sampling; medication effects and heterogeneity limit generalization.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C41", "text": "AMPT depletion induces variable dysphoria correlated with dopamine-binding changes. Dysphoria rather than psychotic trajectory is the main endpoint; obvious subjective effects complicate blind comparisons.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C42", "text": "Amphetamine challenge replicates excess release and transient positive-symptom worsening in a second cohort. Acute subjective challenge, limited registration/expectancy verification and catecholamine specificity; not mesolimbic primacy.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C43", "text": "Depletion-derived excess synaptic dopamine appears in associative striatum, not limbic/sensorimotor regions. Primary endpoint is receptor-binding inference; no selective symptom trajectory experiment.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C44", "text": "Discordant twins and stable patients do not show elevated synthesis versus controls. Low symptom levels, treatment and small sample restrict interpretation as an absolute vulnerability null.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C45", "text": "Medication versus placebo periods alter striatal blood flow with symptom and synthesis associations. Physiological and mediator associations do not selectively isolate D2 necessity or premorbid cause.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C46", "text": "PET challenge shows greater amphetamine-associated binding displacement, with primate calibration support. Binding inference and acute drug response differ from spontaneous human disease dependency.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C47", "text": "Prospective converters have elevated dopamine synthesis before psychosis, strongest in associative striatum. Small transition cohort, transdiagnostic outcomes and no mediator intervention; not proved initiating primacy.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHOD:paragraph2, 1:METHOD:paragraph5, 2:RESULTS:paragraph3, 2:RESULTS:paragraph4. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C48", "text": "Depletion reveals higher dopamine occupancy in untreated patients and predicts later treatment response. Occupancy and treatment-response correlation are not independent randomized symptom-mediator manipulation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C49", "text": "Symptom-matched clozapine-treated TRS patients show lower synthesis than first-line responders. Small groups and differential medications cannot fully separate disease traits from treatment effects.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "C50", "text": "Adolescent Syt11 deficiency or dopamine over-excitation produces persistent behavioural deficits with D2-intervention effects. Age-defined engineered mouse model and social/behavioural proxies cannot establish unselected human mesolimbic primacy.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-12", "note": "" }, { "id": "CSC1", "text": "Imaging, depletion-derived binding and prospective risk studies reproducibly associate striatal dopamine differences with clinical state, with substantial compartment/treatment heterogeneity. The registered SC1 is an association/existence clause; its rating does not claim a causal disease dependency.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 13, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-12", "note": "" }, { "id": "CSC2", "text": "Clinical challenge, drug-dose and occupancy studies support symptom modulation, but this bounded audit has not verified the psychiatry rubric combination of prespecified/registered primary symptom outcomes, credible expectancy controls and selective human D2 mediator manipulation. Occupancy-response correlation alone is insufficient. Γ here records an incompletely crossed strict mechanistic audit gate, not absence of antipsychotic efficacy or evidence that dopamine manipulation has no effects.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 19, 28, 34, 36, 41, 42, 45, 48 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-12", "note": "" }, { "id": "CSC3", "text": "Human mesolimbic primacy in unselected schizophrenia remains unestablished. Associative-striatal findings, response/state heterogeneity and upstream rodent manipulations constrain the claim. Treatment benefit and premorbid synthesis elevation neither identify a universally primary mesolimbic cause nor prove dopamine is irrelevant.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 6, 13, 14, 15, 16, 18, 27, 30, 32, 33, 34, 35, 36, 40, 43, 47, 49, 50 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-12", "note": "" }, { "id": "CH", "text": "Dopamine dysregulation is relevant to psychosis and symptom modulation; unselected mesolimbic D2 primacy is not established.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 47, 43, 40, 13, 14, 10 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-12", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Ozawa C, Bies RR, Pillai N et al. Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial. Journal of clinical psychopharmacology. 2019.", "tier": "A", "kind": "rct", "pmid": "31188232", "doi": "10.1097/JCP.0000000000001046", "url": "https://pubmed.ncbi.nlm.nih.gov/31188232/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID31188232", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC2" ] }, { "n": 2, "citation": "Potkin SG, Keator DB, Kesler-West ML et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS spectrums. 2014.", "tier": "A", "kind": "rct", "pmid": "24073841", "doi": "10.1017/S109285291300059X", "url": "https://pubmed.ncbi.nlm.nih.gov/24073841/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID24073841", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC2" ] }, { "n": 3, "citation": "Moriguchi S, Bies RR, Remington G et al. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Journal of clinical psychopharmacology. 2013.", "tier": "A", "kind": "rct", "pmid": "23899638", "doi": "10.1097/JCP.0b013e3182979a0a", "url": "https://pubmed.ncbi.nlm.nih.gov/23899638/", "status_flags": [ "ErratumIn: PMID25719960" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID23899638", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC2" ] }, { "n": 4, "citation": "Kapur S, Zipursky RB, Remington G et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. The American journal of psychiatry. 1998.", "tier": "A", "kind": "rct", "pmid": "9659858", "doi": "10.1176/ajp.155.7.921", "url": "https://pubmed.ncbi.nlm.nih.gov/9659858/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID9659858", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC2" ] }, { "n": 5, "citation": "Mizuno Y, Bies RR, Remington G et al. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in neuro-psychopharmacology & biological psychiatry. 2012.", "tier": "A", "kind": "rct", "pmid": "22230651", "doi": "10.1016/j.pnpbp.2011.12.013", "url": "https://pubmed.ncbi.nlm.nih.gov/22230651/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID22230651", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC2" ] }, { "n": 6, "citation": "Agid O, Mamo D, Ginovart N et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2007.", "tier": "A", "kind": "rct", "pmid": "17077809", "doi": "10.1038/sj.npp.1301242", "url": "https://pubmed.ncbi.nlm.nih.gov/17077809/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID17077809", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC2", "CSC3" ] }, { "n": 7, "citation": "Zipursky RB, Christensen BK, Daskalakis Z et al. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2005.", "tier": "A", "kind": "rct", "pmid": "16127964", "doi": "10.1177/070674370505000806", "url": "https://pubmed.ncbi.nlm.nih.gov/16127964/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID16127964", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC2" ] }, { "n": 8, "citation": "Takeuchi H, Suzuki T, Bies RR et al. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. The Journal of clinical psychiatry. 2014.", "tier": "A", "kind": "rct", "pmid": "25099201", "doi": "10.4088/JCP.13m08841", "url": "https://pubmed.ncbi.nlm.nih.gov/25099201/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID25099201", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC2" ] }, { "n": 9, "citation": "de Haan L, van Bruggen M, Lavalaye J et al. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. The American journal of psychiatry. 2003.", "tier": "A", "kind": "rct", "pmid": "12562577", "doi": "10.1176/appi.ajp.160.2.303", "url": "https://pubmed.ncbi.nlm.nih.gov/12562577/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID12562577", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC2" ] }, { "n": 10, "citation": "Kapur S, Zipursky R, Jones C et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. The American journal of psychiatry. 2000.", "tier": "A", "kind": "rct", "pmid": "10739409", "doi": "10.1176/appi.ajp.157.4.514", "url": "https://pubmed.ncbi.nlm.nih.gov/10739409/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID10739409", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC2", "CH" ] }, { "n": 11, "citation": "Mamo D, Graff A, Mizrahi R et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. The American journal of psychiatry. 2007.", "tier": "A", "kind": "rct", "pmid": "17728427", "doi": "10.1176/appi.ajp.2007.06091479", "url": "https://pubmed.ncbi.nlm.nih.gov/17728427/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID17728427", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC2" ] }, { "n": 12, "citation": "Kapur S, Zipursky R, Jones C et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Archives of general psychiatry. 2000.", "tier": "A", "kind": "rct", "pmid": "10839333", "doi": "10.1001/archpsyc.57.6.553", "url": "https://pubmed.ncbi.nlm.nih.gov/10839333/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID10839333", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC2" ] }, { "n": 13, "citation": "Egerton A, Murphy A, Donocik J et al. Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). Schizophrenia bulletin. 2021.", "tier": "A", "kind": "primary", "pmid": "32910150", "doi": "10.1093/schbul/sbaa128", "url": "https://pubmed.ncbi.nlm.nih.gov/32910150/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID32910150", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph3, 1:Methods:paragraph4, 2:Results:paragraph11. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC1", "CSC3", "CH" ] }, { "n": 14, "citation": "Kaul I, Sawchak S, Walling DP et al. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA psychiatry. 2024.", "tier": "A", "kind": "rct", "pmid": "38691387", "doi": "10.1001/jamapsychiatry.2024.0785", "url": "https://pubmed.ncbi.nlm.nih.gov/38691387/", "status_flags": [ "ErratumIn: PMID38958995" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID38691387", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph5, 2:Results:paragraph7. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC2", "CSC3", "CH" ] }, { "n": 15, "citation": "Kaul I, Sawchak S, Correll CU et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet (London, England). 2024.", "tier": "A", "kind": "rct", "pmid": "38104575", "doi": "10.1016/S0140-6736(23)02190-6", "url": "https://pubmed.ncbi.nlm.nih.gov/38104575/", "status_flags": [ "ErratumIn: PMID38823993" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID38104575", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC2", "CSC3" ] }, { "n": 16, "citation": "Krystal JH, Kane JM, Correll CU et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet (London, England). 2022.", "tier": "A", "kind": "rct", "pmid": "36528376", "doi": "10.1016/S0140-6736(22)01990-0", "url": "https://pubmed.ncbi.nlm.nih.gov/36528376/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID36528376", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC2", "CSC3" ] }, { "n": 17, "citation": "Prata DP, Mechelli A, Fu CH et al. Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia. Biological psychiatry. 2009.", "tier": "A", "kind": "primary", "pmid": "19054502", "doi": "10.1016/j.biopsych.2008.09.027", "url": "https://pubmed.ncbi.nlm.nih.gov/19054502/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID19054502", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC1" ] }, { "n": 18, "citation": "Niwa M, Kamiya A, Murai R et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron. 2010.", "tier": "A", "kind": "primary", "pmid": "20188653", "doi": "10.1016/j.neuron.2010.01.019", "url": "https://pubmed.ncbi.nlm.nih.gov/20188653/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID20188653", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC3" ] }, { "n": 19, "citation": "Blasi G, Napolitano F, Ursini G et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2011.", "tier": "A", "kind": "primary", "pmid": "21187413", "doi": "10.1073/pnas.1013535108", "url": "https://pubmed.ncbi.nlm.nih.gov/21187413/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID21187413", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC1", "CSC2" ] }, { "n": 20, "citation": "Stenkrona P, Matheson GJ, Halldin C et al. D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients. The international journal of neuropsychopharmacology. 2019.", "tier": "A", "kind": "primary", "pmid": "30958880", "doi": "10.1093/ijnp/pyz017", "url": "https://pubmed.ncbi.nlm.nih.gov/30958880/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID30958880", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC1" ] }, { "n": 21, "citation": "Taylor SF, Koeppe RA, Tandon R et al. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2000.", "tier": "A", "kind": "primary", "pmid": "11063922", "doi": "10.1016/S0893-133X(00)00165-2", "url": "https://pubmed.ncbi.nlm.nih.gov/11063922/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID11063922", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC1" ] }, { "n": 22, "citation": "De Koning MB, Bloemen OJ, Van Duin ED et al. Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. Journal of psychopharmacology (Oxford, England). 2014.", "tier": "A", "kind": "primary", "pmid": "24526133", "doi": "10.1177/0269881113519507", "url": "https://pubmed.ncbi.nlm.nih.gov/24526133/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID24526133", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC1" ] }, { "n": 23, "citation": "Veselinović T, Vernaleken I, Janouschek H et al. The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacology. 2018.", "tier": "A", "kind": "primary", "pmid": "29717334", "doi": "10.1007/s00213-018-4916-6", "url": "https://pubmed.ncbi.nlm.nih.gov/29717334/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID29717334", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC1" ] }, { "n": 24, "citation": "Dahoun T, Nour MM, Adams RA et al. Disrupted-in-schizophrenia 1 functional polymorphisms and D2 /D3 receptor availability: A [11 C]-(+)-PHNO imaging study. Genes, brain, and behavior. 2019.", "tier": "A", "kind": "primary", "pmid": "31264367", "doi": "10.1111/gbb.12596", "url": "https://pubmed.ncbi.nlm.nih.gov/31264367/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID31264367", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1" ] }, { "n": 25, "citation": "Kubota M, Nagashima T, Takano H et al. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia. The international journal of neuropsychopharmacology. 2017.", "tier": "A", "kind": "primary", "pmid": "29016872", "doi": "10.1093/ijnp/pyx063", "url": "https://pubmed.ncbi.nlm.nih.gov/29016872/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID29016872", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC1" ] }, { "n": 26, "citation": "Kumakura Y, Cumming P, Vernaleken I et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007.", "tier": "A", "kind": "primary", "pmid": "17652599", "doi": "10.1523/JNEUROSCI.0805-07.2007", "url": "https://pubmed.ncbi.nlm.nih.gov/17652599/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID17652599", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC1" ] }, { "n": 27, "citation": "Howes OD, Montgomery AJ, Asselin MC et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of general psychiatry. 2009.", "tier": "A", "kind": "primary", "pmid": "19124684", "doi": "10.1001/archgenpsychiatry.2008.514", "url": "https://pubmed.ncbi.nlm.nih.gov/19124684/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID19124684", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC1", "CSC3" ] }, { "n": 28, "citation": "Zhang JP, Robinson DG, Gallego JA et al. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophrenia bulletin. 2015.", "tier": "A", "kind": "primary", "pmid": "26320194", "doi": "10.1093/schbul/sbv116", "url": "https://pubmed.ncbi.nlm.nih.gov/26320194/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID26320194", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC2" ] }, { "n": 29, "citation": "Cassidy CM, Zucca FA, Girgis RR et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proceedings of the National Academy of Sciences of the United States of America. 2019.", "tier": "A", "kind": "primary", "pmid": "30796187", "doi": "10.1073/pnas.1807983116", "url": "https://pubmed.ncbi.nlm.nih.gov/30796187/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID30796187", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC1" ] }, { "n": 30, "citation": "Lenk HÇ, Koch E, O'Connell KS et al. Genome-wide association analysis of treatment resistant schizophrenia for variant discovery and polygenic assessment. Human genomics. 2024.", "tier": "A", "kind": "primary", "pmid": "39334510", "doi": "10.1186/s40246-024-00673-x", "url": "https://pubmed.ncbi.nlm.nih.gov/39334510/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID39334510", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC1", "CSC3" ] }, { "n": 31, "citation": "Veronese M, Santangelo B, Jauhar S et al. A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2021.", "tier": "A", "kind": "primary", "pmid": "32961543", "doi": "10.1038/s41386-020-00866-7", "url": "https://pubmed.ncbi.nlm.nih.gov/32961543/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID32961543", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC1" ] }, { "n": 32, "citation": "Frankle WG, Himes M, Mason NS et al. Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia. Biological psychiatry. 2022.", "tier": "A", "kind": "primary", "pmid": "35791965", "doi": "10.1016/j.biopsych.2022.05.009", "url": "https://pubmed.ncbi.nlm.nih.gov/35791965/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID35791965", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC1", "CSC3" ] }, { "n": 33, "citation": "Boley AM, Perez SM, Lodge DJ. A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. Schizophrenia research. 2014.", "tier": "A", "kind": "primary", "pmid": "24888524", "doi": "10.1016/j.schres.2014.05.005", "url": "https://pubmed.ncbi.nlm.nih.gov/24888524/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID24888524", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC3" ] }, { "n": 34, "citation": "Lipina TV, Niwa M, Jaaro-Peled H et al. Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes, brain, and behavior. 2010.", "tier": "A", "kind": "primary", "pmid": "20618446", "doi": "10.1111/j.1601-183X.2010.00615.x", "url": "https://pubmed.ncbi.nlm.nih.gov/20618446/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID20618446", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC2", "CSC3" ] }, { "n": 35, "citation": "Grimm CM, Aksamaz S, Schulz S et al. Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity. Translational psychiatry. 2018.", "tier": "A", "kind": "primary", "pmid": "30301879", "doi": "10.1038/s41398-018-0268-6", "url": "https://pubmed.ncbi.nlm.nih.gov/30301879/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID30301879", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC3" ] }, { "n": 36, "citation": "Servonnet A, Allain F, Gravel-Chouinard A et al. Dopaminergic mechanisms underlying the expression of antipsychotic-induced dopamine supersensitivity in rats. Neuropharmacology. 2021.", "tier": "A", "kind": "primary", "pmid": "34364897", "doi": "10.1016/j.neuropharm.2021.108747", "url": "https://pubmed.ncbi.nlm.nih.gov/34364897/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID34364897", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC2", "CSC3" ] }, { "n": 37, "citation": "Avram M, Brandl F, Cabello J et al. Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain : a journal of neurology. 2019.", "tier": "A", "kind": "primary", "pmid": "31135051", "doi": "10.1093/brain/awz093", "url": "https://pubmed.ncbi.nlm.nih.gov/31135051/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID31135051", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC1" ] }, { "n": 38, "citation": "Huttunen J, Heinimaa M, Svirskis T et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biological psychiatry. 2008.", "tier": "A", "kind": "primary", "pmid": "17655830", "doi": "10.1016/j.biopsych.2007.04.017", "url": "https://pubmed.ncbi.nlm.nih.gov/17655830/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID17655830", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC1" ] }, { "n": 39, "citation": "Nozaki S, Kato M, Takano H et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophrenia research. 2009.", "tier": "A", "kind": "primary", "pmid": "19056247", "doi": "10.1016/j.schres.2008.11.006", "url": "https://pubmed.ncbi.nlm.nih.gov/19056247/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID19056247", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC1" ] }, { "n": 40, "citation": "Demjaha A, Murray RM, McGuire PK et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. The American journal of psychiatry. 2012.", "tier": "A", "kind": "primary", "pmid": "23034655", "doi": "10.1176/appi.ajp.2012.12010144", "url": "https://pubmed.ncbi.nlm.nih.gov/23034655/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID23034655", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC1", "CSC3", "CH" ] }, { "n": 41, "citation": "Voruganti L, Slomka P, Zabel P et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2001.", "tier": "A", "kind": "primary", "pmid": "11682247", "doi": "10.1016/S0893-133X(01)00263-9", "url": "https://pubmed.ncbi.nlm.nih.gov/11682247/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID11682247", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC2" ] }, { "n": 42, "citation": "Abi-Dargham A, Gil R, Krystal J et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. The American journal of psychiatry. 1998.", "tier": "A", "kind": "primary", "pmid": "9619147", "doi": "10.1176/ajp.155.6.761", "url": "https://pubmed.ncbi.nlm.nih.gov/9619147/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID9619147", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC1", "CSC2" ] }, { "n": 43, "citation": "Kegeles LS, Abi-Dargham A, Frankle WG et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Archives of general psychiatry. 2010.", "tier": "A", "kind": "primary", "pmid": "20194823", "doi": "10.1001/archgenpsychiatry.2010.10", "url": "https://pubmed.ncbi.nlm.nih.gov/20194823/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID20194823", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC1", "CSC3", "CH" ] }, { "n": 44, "citation": "Shotbolt P, Stokes PR, Owens SF et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychological medicine. 2011.", "tier": "A", "kind": "primary", "pmid": "21426628", "doi": "10.1017/S0033291711000341", "url": "https://pubmed.ncbi.nlm.nih.gov/21426628/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID21426628", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC1" ] }, { "n": 45, "citation": "Eisenberg DP, Yankowitz L, Ianni AM et al. Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2017.", "tier": "A", "kind": "primary", "pmid": "28387222", "doi": "10.1038/npp.2017.67", "url": "https://pubmed.ncbi.nlm.nih.gov/28387222/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID28387222", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC1", "CSC2" ] }, { "n": 46, "citation": "Breier A, Su TP, Saunders R et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America. 1997.", "tier": "A", "kind": "primary", "pmid": "9122236", "doi": "10.1073/pnas.94.6.2569", "url": "https://pubmed.ncbi.nlm.nih.gov/9122236/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID9122236", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC1" ] }, { "n": 47, "citation": "Howes OD, Bose SK, Turkheimer F et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. The American journal of psychiatry. 2011.", "tier": "A", "kind": "primary", "pmid": "21768612", "doi": "10.1176/appi.ajp.2011.11010160", "url": "https://pubmed.ncbi.nlm.nih.gov/21768612/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID21768612", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHOD:paragraph2, 1:METHOD:paragraph5, 2:RESULTS:paragraph3, 2:RESULTS:paragraph4. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC1", "CSC3", "CH" ] }, { "n": 48, "citation": "Abi-Dargham A, Rodenhiser J, Printz D et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2000.", "tier": "A", "kind": "primary", "pmid": "10884434", "doi": "10.1073/pnas.97.14.8104", "url": "https://pubmed.ncbi.nlm.nih.gov/10884434/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID10884434", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC1", "CSC2" ] }, { "n": 49, "citation": "Kim E, Howes OD, Veronese M et al. Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2017.", "tier": "A", "kind": "primary", "pmid": "27857125", "doi": "10.1038/npp.2016.258", "url": "https://pubmed.ncbi.nlm.nih.gov/27857125/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID27857125", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC1", "CSC3" ] }, { "n": 50, "citation": "Chen Y, Gu Y, Wang B et al. Synaptotagmin-11 deficiency mediates schizophrenia-like behaviors in mice via dopamine over-transmission. Nature communications. 2024.", "tier": "A", "kind": "primary", "pmid": "39632880", "doi": "10.1038/s41467-024-54604-4", "url": "https://pubmed.ncbi.nlm.nih.gov/39632880/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-12", "status_checked_on": "2026-10-12", "study_id": "PMID39632880", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC3" ] } ], "independence_basis": { "required": false, "lines": [ { "label": "Prospective timing", "sources": [ 47, 27 ], "excludes_error": "Constrains dopamine elevation being measured only after frank psychosis, but shared recruitment/research program and prodromal upstream processes remain." }, { "label": "Human challenge/occupancy", "sources": [ 48, 42, 10, 45 ], "excludes_error": "Constrains pure static imaging association, but acute subjective effects, receptor specificity and outcome registration require verification." }, { "label": "Response/state boundaries", "sources": [ 40, 49, 13, 37 ], "excludes_error": "Constrains universal excess and response assumptions; selected groups, medication and overlapping cohorts remain." }, { "label": "Muscarinic symptom interventions", "sources": [ 15, 14 ], "excludes_error": "Tests clinical efficacy without direct D2 antagonism, but no selective dopamine mediation/dispensability readout and shared sponsor/program." } ], "shared_failure_mode_checked": true, "note": "FDOPA studies share tracer/model assumptions and sometimes recruitment or research teams. EMERGENT trials are distinct randomizations within one sponsor program; they are not independent mechanism-identification experiments. STRATA is a genuine multicentre contradictory classifier result. Orthogonality does not repair missing exact-scope mediator controls." }, "consensus_validation": { "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Consensus Pro signed-in browser; observed response and citation-link mappings", "queries": [ "https://consensus.app/search/mesolimbic-dopamine-schizophrenia/O4UuYpiZT8uZvOsbnNLBXQ/" ], "query_record_note": "Observed thread URL and visible request/response in raw receipt; no unobserved query payload reconstructed.", "primary_comparison_count": 4, "primary_comparisons": [ { "pmid": "21768612", "doi": "10.1176/appi.ajp.2011.11010160", "source_type": "primary study report", "study_group": "PMID21768612", "access_depth": "full_text_partial", "consensus_aspect": "Dopamine abnormalities precede some psychosis transitions.", "result_comparison": "Original prospective study body supports a striatal association in a small converter group. The limbic comparison is nonsignificant; a prospective association is not a selective mesolimbic necessity test.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/21768612/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\examinations\\resumption-34-51-1400.json" ], "body_receipts": [ "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\21768612-s1-p2-5.json", "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\21768612-s2-p3-4.json" ] }, { "pmid": "32910150", "doi": "10.1093/schbul/sbaa128", "source_type": "primary study report", "study_group": "PMID32910150", "access_depth": "full_text_partial", "consensus_aspect": "Treatment resistance can distinguish dopamine-related illness.", "result_comparison": "Original multicentre STRATA body finds no responder/nonresponder dopamine difference. A settled diagnostic classifier cannot be inferred from earlier small studies.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/32910150/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\examinations\\resumption-0-17-1050.json" ], "body_receipts": [ "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\32910150-s1-p3-4.json", "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\32910150-s2-p11.json" ] }, { "pmid": "38691387", "doi": "10.1001/jamapsychiatry.2024.0785", "source_type": "primary study report", "study_group": "PMID38691387", "access_depth": "full_text_partial", "consensus_aspect": "Muscarinic treatment can improve psychotic symptoms.", "result_comparison": "Original EMERGENT-3 body verifies registration and a positive PANSS endpoint, but excludes treatment-resistant history and does not measure a selective dopamine mediator. It does not establish efficacy in TRS or dopamine dispensability.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/38691387/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\examinations\\resumption-0-17-1050.json" ], "body_receipts": [ "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\38691387-s1-p0-1-4-5.json", "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\38691387-s2-p7.json" ] }, { "pmid": "10739409", "doi": "10.1176/appi.ajp.157.4.514", "source_type": "primary study report", "study_group": "PMID10739409", "access_depth": "abstract_metadata", "consensus_aspect": "D2 occupancy supports a symptom-treatment relationship.", "result_comparison": "Original primary abstract links occupancy to clinical response and adverse effects. This bounded audit does not verify a preregistered selective mesolimbic mediator/trajectory experiment; failure to verify that provenance is not failure of antipsychotic efficacy.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/10739409/", "source_examination_receipts": [ "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\examinations\\resumption-0-17-1050.json" ], "body_receipts": [] } ], "grade_changed": false, "grade_change_note": "Comparison does not introduce an independently blinded regrade; bounded case adjudication remains source-based.", "raw_receipts": [ { "path": "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\consensus-browser-2026-10-11.json", "sha256": "11361cfb53ec17ecdefdec07e364ad532090ed879010e870ca4262f3db59ab4a" } ], "independent_blinded_audit": false, "cutoff": "2026-10-09", "completed_utc": "2026-10-12T02:11:33.494044+00:00", "conclusion": "Specific qualifiers and endpoint hierarchy above are retained in the evidence cards; AI wording does not override the original sources." } }